logo-loader
viewCytoDyn Inc.

CytoDyn’s impressive run continues for leronlimab in metastatic triple-negative breast cancer and metastatic breast cancer

Data from the first patient with mTNBC shows no detectable circulating tumor cells in the peripheral blood after 15 weeks

CytoDyn Inc. - CytoDyn’s impressive run continues for leronlimab in metastatic triple-negative breast cancer and metastatic breast cancer
A second patient with stage four metastatic breast cancer showed 50% shrinkage in the primary tumor and no new signs of metastasis in the brain after being treated with leronlimab as a monotherapy

CytoDyn Inc (OTCMKTS:CYDY), a late-stage biotechnology company, revealed additional “promising results” Wednesday from its clinical trials evaluating its lead drug leronlimab (PRO 140) for the treatment of metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). 

In a statement, the company said that new data from the first patient enrolled in the company’s metastatic triple-negative breast (mTNBC) Phase 1b/2 trial continues to show “no detectable levels of circulating tumor cells” in the peripheral blood following “15 weeks of treatment with leronlimab in combination with carboplatin.”

Similarly, the second patient enrolled through an emergency investigational new drug (IND) process with metastatic stage four breast cancer that had metastasized to the liver, lung and brain, showed “a 50% shrinkage of the primary tumor and no new metastasis in the brain” after treatment with leronlimab as a monotherapy.

READ: CytoDyn files for breakthrough therapy status for leronlimab in metastatic triple-negative breast cancer

The patient was previously treated with pertuzumab and trastuzumab for over a year and a half. This patient has been taking leronlimab since November 25, 2019, with one 700 mg dose each week.

“Recent testing of the first patient demonstrated continued absence of circulating tumor cells in all blood tubes with only one cancer-associated macrophage-like cells in one of two tubes. In the second patient, the follow up brain scan conducted on January 17, showed that the largest brain lesion had a greater than 4-fold reduction in size,” said IncellDx founder CEO Bruce Patterson, who is both a diagnostic partner and advisor to CytoDyn.

Patterson noted that other smaller lesions on the second patient’s brain have not changed in size and “cerebral edema remains at decreased levels” since the last imaging studies.

“Taken together, these results suggest continued response of both primary and metastatic tumors to treatment with leronlimab for both the first and second patient,” he added.

Meanwhile, CytoDyn CEO Nader Pourhassan, said the company was “thrilled” to see the additional data that further supported leronlimab as a potential treatment option for patients with triple-negative breast cancer and metastatic breast cancer.

“As a company, we look forward to continuing our work in the oncology space and developing a potentially safe and effective treatment option for patients suffering from this deadly disease,” said Dr Pourhassan.

Triple-Negative Breast Cancer

Triple-negative breast cancer is a type of breast cancer characterized by the absence of the three most common types of receptors in the cancer tumor known to fuel most breast cancer – estrogen receptors, progesterone receptors and the hormone epidermal growth factor receptor 2 (HER-2) gene. It occurs in about 20% of diagnosed breast cancers and can be more aggressive and likely to spread and recur. Since the triple negative tumor cells lack these receptors, common treatments for breast cancer such as hormone therapy and drugs that target estrogen and progesterone are ineffective. Currently, there are no targeted therapies approved to treat triple negative breast cancer.

CytoDyn, based in Vancouver, Washington, is developing leronlimab to battle multiple diseases. The company has filed an IND application and a Phase 2 clinical trial protocol with the US Food and Drug Administration (FDA) for leronlimab to treat patients with NASH.

Leronlimab has also already completed nine clinical trials and been given to 800 patients in HIV treatment programs, without a single drug-related serious adverse event.

The FDA has granted Fast Track designation to leronlimab for a combination therapy with Highly Active Antiretroviral Therapy for HIV-infected patients and for metastatic triple-negative breast cancer. 

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive 

Quick facts: CytoDyn Inc.

Price: 2.94 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.43 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CytoDyn to work with Mexican National Institutes of Health to treat...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has plans to work with the Mexican National Institutes of Health on a trial of leronlimab for severe coronavirus patients in the country. Pourhassan says the initial trial is expected to include about 30 patients. After...

2 weeks ago

3 min read